Finoriq research workspace
Arbutus Biopharma Corp (ABUS) Institutional Holdings & 13F Ownership
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel. Review ABUS institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
- Company
- Arbutus Biopharma Corp (ABUS)
- Ticker
- ABUS
- Market Cap
- $878.1M
- Latest Price
- $4.445
- Industry
- Biotech & Pharma
Arbutus Biopharma Corp (ABUS) Top Institutional Holders
Top current 13F holders indexed for Arbutus Biopharma Corp (ABUS). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Joel GreenblattCIK 0001510387 | $77,945 | 0.0% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.